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Dear Editor,
We read with interest the Clinical Consensus Recommen-
dation about screening and prevention of preeclampsia
published by De Oliveira et al.1 The authors recommend
that identification of high-risk women should be based on
maternal risk factors alone, and that universal treatment (of
all pregnant women) with aspirin at a dose of 100mg should
be considered in low- and middle-income countries. In this
letter, we express our concerns and disagreement with these
strategies.
The association of certain maternal risk factors with an
increased risk of preeclampsia development is well known,
and several risk scoring systems have been recommended by
Obstetric societies around the world, such as the National
Institute for Health and Care Excellence (NICE) criteria in the
United Kingdom, and the American College of Obstetrician
and Gynecologists (ACOG) in the United States. Such scoring
systems are based on experts’ opinions and low levels of
evidence, attribute similar weights to very different risk
factors, and perform poorly in the clinical practice.2 Recent
large studies2 have shown that such methods fail to identify
as high-risk 60% to 70% of women who will later develop
preeclampsia. Furthermore, physician compliance with
these recommendations is low, with only 20% to 30% of
high-risk women receiving aspirin prophylaxis.2,3 On the
other hand, combined screening with individual risk calcu-
lation by incorporating risk factors, mean arterial blood
pressure, uterine artery Doppler studies, and placental
growth factor (PlGF) far outperforms risk scoring, identifying
as high-risk about three quarters of womenwhowill develop
preterm preeclampsia, and 90% of those destined to develop
early-onset disease.4,5 In addition, combined screening is
more cost-effective,6 and is associated with nearly total




© 2021. Federação Brasileira de Ginecologia e Obstetrícia. All rights
reserved.
This is an open access article published by Thieme under the terms of the
Creative Commons Attribution License, permitting unrestricted use,
distribution, and reproduction so long as the original work is properly cited.
(https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de
Janeiro, RJ, CEP 20270-135, Brazil




technologies is common in Medicine, and translation of
research into clinical practice usually takes a long time,7
most components of combined screening, such as the mea-
surement of arterial blood pressure and ultrasound are
readily available and widely in use in most settings (even
in low/middle-income countries). Simplified versions of the
algorithm (for example, without biochemical markers) out-
performed clinical history even in middle-income countries
such as Brazil,8,9 and could be rapidly implemented with
minimal or no increase in cost, and lead to a significant
increase in the detection of high-risk women who would
benefit from aspirin prophylaxis and likely be missed by risk
scoring screening.
As appealing as the suggestion to give aspirin to all
pregnant women given its relative safety and low cost
may be, a strategy of universal aspirin use has not been
properly assessed in adequately-powered prospective
studies.10 Pregnant women are naturally resistant to medi-
cation use in the absence of convincing medical indication,
and such an approach would likely be associated with low
adherence to treatment.10 The strong effect of aspirin in the
prevention of preeclampsia in high-risk populations11 may
not be observed when the treatment is recommended
to the entire obstetric population, and side effects will
inevitably become more frequent if millions of women
are treated. Indeed, data from a previous study on
universal aspirin prophylaxis demonstrated no clear treat-
ment benefit,12,13 increased risk of postpartum hemor-
rhage,14 and other hemorrhagic events,12 as well as low
adherence to treatment.12 We argue that early combined
prediction with the full or simplified versions of the algo-
rithm for individual risk calculation is feasible in low- and
middle-income countries, and should be the preferred
method of screening whenever possible, in line with recent
recommendations from the International Federation of
Gynecology and Obstetrics (FIGO),15 the International Soci-
ety for the Study of Hypertension in Pregnancy (ISSHP),16
and the International Society of Ultrasound in Obstetrics
and Gynecology.17
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